Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease

Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common cause of dementia. Fingolimod has previously shown beneficial effects in different animal models of AD. However, it has shown contradictory effects when it has been applied at early disease stages. Our objective was to evaluate fingolimod in two different...

Full description

Bibliographic Details
Main Authors:	Pablo Bascuñana, Mirjam Brackhan, Luisa Möhle, Jingyun Wu, Thomas Brüning, Ivan Eiriz, Baiba Jansone, Jens Pahnke
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Biomolecules
Subjects:	FTY720 fingolimod Gilenya APPPS1 Alzheimer’s disease amyloid beta
Online Access:	https://www.mdpi.com/2218-273X/13/2/331

Similar Items

Age-Related Transcriptional Deregulation of Genes Coding Synaptic Proteins in Alzheimer's Disease Murine Model: Potential Neuroprotective Effect of Fingolimod
by: Henryk Jęśko, et al.
Published: (2021-07-01)

Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner
by: Abhisarika Patnaik, et al.
Published: (2020-04-01)

Fingolimod Augments Monomethylfumarate Killing of GBM Cells
by: Paul Dent, et al.
Published: (2020-01-01)

Corrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM Cells
by: Paul Dent, et al.
Published: (2020-04-01)

Fingolimod does not prevent syndecan-4 shedding from the endothelial glycocalyx in a cultured human umbilical vein endothelial cell model of vascular injury
by: Elissa M. Milford, et al.
Published: (2022-08-01)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
by: Tony Sehr, et al.
Published: (2020-05-01)

A case of Posterior Reversible Encephalopathy Syndrome (PRES) associated with Gilenya® (Fingolimod) treatment for Multiple Sclerosis (MS).
by: Hans eLindå, et al.
Published: (2015-03-01)

Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells
by: Ahmet Eken, et al.
Published: (2019-02-01)

Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis
by: Nikolaos Petsas, et al.
Published: (2019-03-01)

Effect of immunomodulator, fingolimod, on ischemia reperfusion testicular injury in rats: Targeting the role of sphingolipid rheostat (fingolimod on I/R induced testicular injury)
by: Marwa N. Emam, et al.
Published: (2017-06-01)

Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis
by: Kathrin Bail, et al.
Published: (2017-07-01)

Fingolimod (FTY720) Preserves High Energy Phosphates and Improves Cardiac Function in Heterotopic Heart Transplantation Model
by: Naseer Ahmed, et al.
Published: (2020-09-01)

Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod
by: Fabian Maass, et al.
Published: (2021-02-01)

Protein phosphatase 2A regulates xanthine oxidase-derived ROS production in macrophages and influx of inflammatory monocytes in a murine gout model
by: Sandy Elsayed, et al.
Published: (2022-11-01)

Sphingosine-1-Phosphate: Boon and Bane for the Brain
by: Gerhild van Echten-Deckert, et al.
Published: (2014-06-01)

Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities
by: Andrea C. Diaz Diaz, et al.
Published: (2022-07-01)

Anti-Inflammatory Treatment with FTY720 Starting after Onset of Symptoms Reverses Synaptic Deficits in an AD Mouse Model
by: Georgia-Ioanna Kartalou, et al.
Published: (2020-11-01)

Sphingosine Kinase-1 Is Overexpressed and Correlates with Hypoxia in Osteosarcoma: Relationship with Clinicopathological Parameters
by: Anne Gomez-Brouchet, et al.
Published: (2022-01-01)

Alterations in the transcriptional profile of genes related to glutamatergic signalling in animal models of Alzheimer’s disease. The effect of fingolimod
by: Grzegorz Sulkowski, et al.
Published: (2022-03-01)

Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod
by: Yasuyuki Kihara, et al.
Published: (2022-06-01)

The Effects of the S1P Receptor Agonist Fingolimod (FTY720) on Central and Peripheral Myelin in Twitcher Mice
by: Sibylle Béchet, et al.
Published: (2024-03-01)

In silico Docking Studies of Fingolimod and S1P1 Agonists
by: Alexander Marciniak, et al.
Published: (2020-03-01)

Adhesion molecule L1 binds to amyloid beta and reduces Alzheimer's disease pathology in mice
by: Nevena Djogo, et al.
Published: (2013-08-01)

Therapeutic approach to mite-induced intractable dermatitis using novel immunomodulator FTY720 ointment (fingolimod) in NC/Nga mice
by: Takumi Tsuji, et al.
Published: (2016-04-01)

Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases
by: Sara Grassi, et al.
Published: (2019-07-01)

Fingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
by: Masoud Etemadifar, et al.
Published: (2017-02-01)

Role of sphingosine 1-phosphate (S1P) and effects of fingolimod, an S1P receptor 1 functional antagonist in lymphocyte circulation and autoimmune diseases
by: Kenji Chiba, et al.
Published: (2014-11-01)

The protective role of FTY720 in promoting survival of allograft fat in mice
by: Yi Yi, et al.
Published: (2022-09-01)

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients
by: S.I. Park, et al.
Published: (2005-05-01)

Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti‐amyloid therapy
by: Jeffrey Fessel
Published: (2022-01-01)

FTY720 decreases ceramides levels in the brain and prevents memory impairments in a mouse model of familial Alzheimer’s disease expressing APOE4
by: Simone M. Crivelli, et al.
Published: (2022-08-01)

Induction of Lysosomal Membrane Permeabilization Is a Major Event of FTY720-Mediated Non-Apoptotic Cell Death in Human Glioma Cells
by: Kyoung-jin Min, et al.
Published: (2020-11-01)

Vesicle Fusion as a Target Process for the Action of Sphingosine and Its Derived Drugs
by: José Villanueva, et al.
Published: (2022-01-01)

The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection
by: Alessandra Gonçalves Commodaro, et al.
Published: (2012-07-01)

ORMDL3 overexpression facilitates FcεRI‐mediated transcription of proinflammatory cytokines and thapsigargin‐mediated PERK phosphorylation in RBL‐2H3 cells
by: Kazuhiro Ogi, et al.
Published: (2021-12-01)

Regulation of PP2A by Sphingolipid Metabolism and Signaling
by: Joshua eOaks, et al.
Published: (2015-01-01)

Toxicidad hepática por fingolimod
by: juan sebastian theran leon, et al.
Published: (2024-02-01)

Fingolimod in children with Rett syndrome: the FINGORETT study
by: Yvonne Naegelin, et al.
Published: (2021-01-01)

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
by: Miraç Ayşen Ünsal
Published: (2019-03-01)

Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab
by: Florian Ottenlinger, et al.
Published: (2016-11-01)